Johnson & Johnson

NYSE JNJ

Johnson & Johnson Price to Earnings Ratio (P/E) on January 14, 2025: 23.73

Johnson & Johnson Price to Earnings Ratio (P/E) is 23.73 on January 14, 2025, a 115.80% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Johnson & Johnson 52-week high Price to Earnings Ratio (P/E) is 27.43 on October 23, 2024, which is 15.56% above the current Price to Earnings Ratio (P/E).
  • Johnson & Johnson 52-week low Price to Earnings Ratio (P/E) is 9.03 on May 28, 2024, which is -61.94% below the current Price to Earnings Ratio (P/E).
  • Johnson & Johnson average Price to Earnings Ratio (P/E) for the last 52 weeks is 14.48.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NYSE: JNJ

Johnson & Johnson

CEO Mr. Joaquin Duato
IPO Date Jan. 2, 1943
Location United States
Headquarters One Johnson & Johnson Plaza
Employees 131,900
Sector Health Care
Industries
Description

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Similar companies

MRK

Merck & Co., Inc.

USD 99.65

-1.32%

BMY

Bristol-Myers Squibb Company

USD 55.74

0.69%

PFE

Pfizer Inc.

USD 26.41

-1.46%

LLY

Eli Lilly and Company

USD 744.91

-6.59%

ABBV

AbbVie Inc.

USD 175.55

-0.67%

GILD

Gilead Sciences, Inc.

USD 91.00

1.18%

AMGN

Amgen Inc.

USD 267.10

-1.14%

StockViz Staff

January 15, 2025

Any question? Send us an email